Swedish Growth Leaders With High Insider Stakes June 2024

In This Article:

As global markets experience mixed signals with regions showing varied economic data, Sweden's market remains a point of interest for investors looking for growth opportunities. In this environment, companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those closest to the business in its growth prospects and governance.

Top 10 Growth Companies With High Insider Ownership In Sweden

Name

Insider Ownership

Earnings Growth

CTT Systems (OM:CTT)

16.9%

21.6%

BioArctic (OM:BIOA B)

35.1%

50.5%

Sileon (OM:SILEON)

33.3%

109.3%

KebNi (OM:KEBNI B)

37.8%

90.4%

InCoax Networks (OM:INCOAX)

17.9%

104.9%

Calliditas Therapeutics (OM:CALTX)

11.6%

53%

Egetis Therapeutics (OM:EGTX)

17.6%

98.2%

edyoutec (NGM:EDYOU)

14.6%

63.1%

Yubico (OM:YUBICO)

37.5%

42.5%

SaveLend Group (OM:YIELD)

24.9%

103.4%

Click here to see the full list of 82 stocks from our Fast Growing Swedish Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

CTT Systems

Simply Wall St Growth Rating: ★★★★★★

Overview: CTT Systems AB, based in Sweden, specializes in designing, manufacturing, and selling humidity control systems for aircraft globally, with a market capitalization of SEK 4.82 billion.

Operations: The company generates its revenue primarily from the Aerospace & Defense segment, totaling SEK 314.20 million.

Insider Ownership: 16.9%

Return On Equity Forecast: 44% (2027 estimate)

CTT Systems, a leader in aircraft cabin humidification systems, recently showcased strong market interest at the 2024 Aircraft Interiors Show. With exclusive agreements to supply Airbus and Boeing, CTT confirmed new orders for its Humidifier Onboard Business class from several airlines. Despite an unstable dividend track record, CTT's revenue and earnings are expected to grow significantly above the Swedish market average. Insider transactions over the last three months also reflect more buying than selling by company insiders, indicating confidence in CTT's future performance.

OM:CTT Earnings and Revenue Growth as at Jun 2024
OM:CTT Earnings and Revenue Growth as at Jun 2024

Egetis Therapeutics

Simply Wall St Growth Rating: ★★★★★★

Overview: Egetis Therapeutics AB, a Swedish pharmaceutical company, specializes in advancing late-stage development projects aimed at treating serious diseases within the orphan drug segment, with a market capitalization of SEK 2.65 billion.

Operations: The company generates revenue primarily from its Emcitate segment, which brought in SEK 62.90 million.